Evidence map›Paper›PMID 40028401›Full record

ArticleTurkish journal of physical medicine and rehabilitation2024

Botulinum toxin type A treatment for persistent neuropathic pain in the soles after cervical spinal cord injury: A case report.

Alper Mengi, Bengi Gül Türk, Ugur Uygunoglu

Abstract readCase Reports
In one paragraph

Article in Turkish journal of physical medicine and rehabilitation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alper MengiDepartment of Pain Management, Sultan 1st Murat State Hospital, Edirne, Türkiye.ORCID 0000-0003-0898-764X
Bengi Gül TürkDepartment of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.ORCID 0000-0003-1839-5971
Ugur UygunogluDepartment of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.ORCID 0000-0003-2866-4004

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subcutaneous botulinum toxin type A is recommended for neuropathic pain at the level of spinal cord injury. Herein, we present a 42-year-old female patient who presented to our outpatient clinic with neuropathic pain in the soles for eight years due to cervical long-segment myelitis. The patient had previously received various ineffective oral medications for the symptoms. Botulinum toxin type A was injected subcutaneously into bilateral soles. The patient was evaluated in the first, second, third, fourth, and sixth months after the injection. The daytime and nighttime Visual Analog Scale, Neuropathic Pain Questionnaire, Short Form-36, and Beck Depression Inventory scores improved during follow-up.

Indexed as

Botulinum toxinneuropathic painpain managementspinal cord injurytreatment.

Identifiers

PMID40028401
PMCPMC11868860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.